A
Ascentage Pharma
China-based clinical-stage biopharmaceutical company
About Ascentage Pharma
Ascentage Pharma is a global biopharmaceutical company that specializes in developing cutting-edge therapies for cancer and age-related diseases. The company operates in the pharmaceutical market, serving clients such as hospitals, clinics, and other healthcare providers. Their business model revolves around the research, development, and commercialization of innovative drugs.
Ascentage Pharma has secured exclusive global licensing rights for several patents related to PPI and cell apoptosis from the University of Michigan. This allows the company to develop and market unique therapies that can potentially revolutionize the treatment of various diseases.
In addition, the company has established strategic partnerships with renowned institutions like MD Anderson Cancer Center and Acerta Pharma. These collaborations involve preclinical and clinical research on compounds developed by Ascentage Pharma, such as APG-1252, APG-2575, APG-1387, APG-115, and HQP1351. These compounds are being studied for their potential in treating various types of cancer.
Ascentage Pharma also collaborates with UNITY Biotechnology to explore the development of molecules from their Bcl-2/Bcl-xL/ Mcl-1 inhibitor library for treating age-related diseases. This partnership allows Ascentage Pharma to validate patent combinations, enhance research capabilities, and expand commercialization rights to global markets and other therapeutic areas.
The company generates revenue through the sale of its approved drugs, licensing its patented technologies, and through strategic partnerships.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- Suzhou Shi, China
- Listing
- IPO 2019
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
BioVenture Capital- YCYuanMing Capital
Oriza Holdings
State Development & Investment Corporation (SDIC)
Series B and later3 investors entered at this stage
CCB International
ArrowMark Partners
Takeda Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
151 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ascentage Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ascentage Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.